NAJIMU AKANJI: Open Payments
NPI 1780391482 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$818 in 43 payments from 12 companies in 2025. Trend: 2023 $465 · 2024 $552 · 2025 $818
Food & beverage: $818
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 16 | $253 |
| Janssen Pharmaceuticals, Inc | 4 | $101 |
| E.R. Squibb & Sons, L.L.C. | 4 | $91 |
| Almatica Pharma LLC | 5 | $79 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $76 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $45 |
| Axsome Therapeutics, Inc. | 2 | $41 |
| Neurocrine BioSciences, Inc. | 1 | $33 |
| Indivior Inc. | 1 | $32 |
| Sage Therapeutics, LLC | 2 | $31 |
Products named: REXULTI, SPRAVATO, COBENFY, LOREEV XR, TRINTELLIX, ABILIFY ASIMTUFII, CAPLYTA, Auvelity.
Industry payments across NV — which companies pay providers there.
